Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

Nearly half of participants in a weight loss program who initiated an antiobesity medication and who consumed alcohol ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay ...

Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...